Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
UVI 3003 REF: IN-DA008GQ3CAS: 847239-17-2 | 98% | To inquire | Tue 07 Jan 25 | |
UVI 3003 REF: 54-BISN0065CAS: 847239-17-2 | 98% | 67.00 € | Tue 07 Jan 25 | |
UVI 3003 REF: TM-T17209CAS: 847239-17-2 | 99.94% | 35.00 €~594.00 € | Mon 13 Jan 25 | |
UVI 3003 REF: 3D-XIB23917CAS: 847239-17-2 | Min. 95% | To inquire | Tue 18 Feb 25 |
Ref: IN-DA008GQ3
1mg | 50.00 € | ||
5mg | 108.00 € | ||
10mg | 149.00 € | ||
25mg | 211.00 € | ||
50mg | 473.00 € | ||
100mg | 569.00 € | ||
250mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Ref: 54-BISN0065
5mg | 67.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
UVI 3003
CAS:847239-17-2
UVI 3003 blocks retinoid X receptor (RXRα) in Xenopus/human Cos7 cells; IC50: 0.22/0.24 μM.
Formula:
C28H36O4
Purity:
99.94%
Color and Shape:
Solid
Molecular weight:
436.58
Ref: TM-T17209
1mg | 35.00 € | ||
2mg | 52.00 € | ||
5mg | 74.00 € | ||
10mg | 118.00 € | ||
25mg | 237.00 € | ||
50mg | 398.00 € | ||
100mg | 594.00 € | ||
1mL*10mM (DMSO) | 85.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025
UVI 3003
CAS:847239-17-2
UVI 3003 is a drug that is being developed for the treatment of cancer. It …
Formula:
C28H36O4
Purity:
Min. 95%
Molecular weight:
436.58 g/mol
Ref: 3D-XIB23917
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025